KR20220151038A - 코로나바이러스 감염 예방를 위한 조성물 - Google Patents

코로나바이러스 감염 예방를 위한 조성물 Download PDF

Info

Publication number
KR20220151038A
KR20220151038A KR1020227038215A KR20227038215A KR20220151038A KR 20220151038 A KR20220151038 A KR 20220151038A KR 1020227038215 A KR1020227038215 A KR 1020227038215A KR 20227038215 A KR20227038215 A KR 20227038215A KR 20220151038 A KR20220151038 A KR 20220151038A
Authority
KR
South Korea
Prior art keywords
day
oleandrin
infection
extract
virus
Prior art date
Application number
KR1020227038215A
Other languages
English (en)
Korean (ko)
Inventor
로버트 에이. 뉴먼
오티스 씨. 애딩턴
리차드 오비소
Original Assignee
피닉스 바이오테크놀러지 인코포레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/895,920 external-priority patent/US10729735B1/en
Application filed by 피닉스 바이오테크놀러지 인코포레이티드. filed Critical 피닉스 바이오테크놀러지 인코포레이티드.
Publication of KR20220151038A publication Critical patent/KR20220151038A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020227038215A 2020-03-31 2020-07-14 코로나바이러스 감염 예방를 위한 조성물 KR20220151038A (ko)

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
US202063002735P 2020-03-31 2020-03-31
US63/002,735 2020-03-31
US202063010246P 2020-04-15 2020-04-15
US63/010,246 2020-04-15
US202063014294P 2020-04-23 2020-04-23
US63/014,294 2020-04-23
US202063017263P 2020-04-29 2020-04-29
US63/017,263 2020-04-29
US202063021512P 2020-05-07 2020-05-07
US63/021,512 2020-05-07
US202063029530P 2020-05-24 2020-05-24
US63/029,530 2020-05-24
US202063034800P 2020-06-04 2020-06-04
US63/034,800 2020-06-04
US16/895,920 2020-06-08
US16/895,920 US10729735B1 (en) 2016-09-14 2020-06-08 Method and compostitions for treating coronavirus infection
US202063042656P 2020-06-23 2020-06-23
US63/042,656 2020-06-23
US202063051576P 2020-07-14 2020-07-14
KR1020207026847A KR102464428B1 (ko) 2020-03-31 2020-07-14 코로나바이러스 감염 치료를 위한 방법 및 조성물
PCT/US2020/042009 WO2021201903A1 (en) 2020-03-31 2020-07-14 Method and compositions for treating coronavirus infection
US63/051,576 2020-07-14

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207026847A Division KR102464428B1 (ko) 2020-03-31 2020-07-14 코로나바이러스 감염 치료를 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20220151038A true KR20220151038A (ko) 2022-11-11

Family

ID=77930101

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207026847A KR102464428B1 (ko) 2020-03-31 2020-07-14 코로나바이러스 감염 치료를 위한 방법 및 조성물
KR1020227038215A KR20220151038A (ko) 2020-03-31 2020-07-14 코로나바이러스 감염 예방를 위한 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207026847A KR102464428B1 (ko) 2020-03-31 2020-07-14 코로나바이러스 감염 치료를 위한 방법 및 조성물

Country Status (8)

Country Link
JP (2) JP7153083B2 (zh)
KR (2) KR102464428B1 (zh)
IL (2) IL277315B (zh)
MX (2) MX2020009095A (zh)
RU (1) RU2020130238A (zh)
SG (1) SG11202105728YA (zh)
TW (2) TWI753747B (zh)
WO (1) WO2021201903A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351149B2 (en) * 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
JP2024532149A (ja) * 2021-08-16 2024-09-05 フェニックス・バイオテクノロジー・インコーポレイテッド 動物ウイルス感染を治療するための方法および組成物
WO2023212353A1 (en) * 2022-04-29 2023-11-02 Emory University Viral entry inhibitors derived from botanicals
CN115364136A (zh) * 2022-09-05 2022-11-22 深圳市药品检验研究院（深圳市医疗器械检测中心） 景天科植物提取物在制备抗新型冠状病毒和流感病毒感染药物中的应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1394196A (en) 1971-10-03 1975-05-14 Hisamitsu Pharmaceutical Co Process for isolating oleandrin from nerium odorum
PT84857B (pt) 1986-05-13 1990-02-08 Huseyin Ziya Ozel Processo para a preparacao de extractos de plantas da especie nerium e de composicoes farmaceuticas que os contem
JPS6333341A (ja) * 1986-07-28 1988-02-13 Seitetsu Kagaku Co Ltd 配糖体の処理方法
US5236132A (en) 1992-01-03 1993-08-17 Vortec, Inc. Gradient-force comminuter/dehydrator apparatus and method
US5598979A (en) 1995-04-20 1997-02-04 Vortec, Inc. Closed loop gradient force comminuting and dehydrating system
CA2191923C (en) 1996-12-03 2000-10-24 Ji-Won Yoon Portulaca oleracea and tumor cell growth
WO1999059578A1 (en) 1998-05-19 1999-11-25 Research Development Foundation Triterpene compositions and methods for use thereof
CA2354037A1 (en) 1998-09-24 2000-03-30 Ozelle Pharmaceuticals, Inc. Extract of nerium species, pharmaceutical composition thereof and methods for preparation thereof
US6517015B2 (en) 2000-03-21 2003-02-11 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
AU2001284946B2 (en) 2000-08-18 2007-02-01 Advanced Life Sciences Inc. Prodrugs of betulinic acid derivatives for the treatment of cancer and HIV
US6715705B2 (en) 2001-03-16 2004-04-06 Frank F. Rowley, Jr. Two-stage comminuting and dehydrating system and method
DE60204078T2 (de) 2001-04-09 2006-01-26 Loders Croklaan B.V. Konzentrat von Triterpenen
EP2567625A1 (en) 2001-05-11 2013-03-13 University Of Ottawa Preparation containing betulinic acid, obtained from a plant of the family Marcgraviaceae
CA2443630A1 (en) 2001-06-18 2002-12-27 S.A.V. Virex Co Ltd. Nerium oleander extract, compositions containing the nerium oleander l. extract and a method of preparation of this extract
US20040082521A1 (en) 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
EP1585504A4 (en) 2002-11-06 2009-07-15 Azaya Therapeutics Inc LIPOSOMAL PREPARATIONS OF PHARMACEUTICAL AGENTS STABILIZED BY PROTEINS
US20050026849A1 (en) 2003-03-28 2005-02-03 Singh Chandra U. Water soluble formulations of digitalis glycosides for treating cell-proliferative and other diseases
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
US7118508B2 (en) 2004-07-28 2006-10-10 General Motors Corporation Planetary transmissions having three interconnected gear members and clutched input members
WO2006036337A2 (en) 2004-08-13 2006-04-06 Biolase Technology, Inc. Laser handpiece architecture and methods
KR101068259B1 (ko) 2005-02-09 2011-09-28 프레세니어스 카비 온콜로지 리미티드 헤테로사이클기에 고리－축합된 신규 베툴린산 유도체
US20090076290A1 (en) 2005-03-29 2009-03-19 Regents Of The University Of Minnesota Selective oxidation of triterpenes employing tempo
US20060252733A1 (en) 2005-04-07 2006-11-09 Novelix Pharmaceuticals, Inc. Betulin, betulin derivatives, betulinic acid and betulinic acid derivatives as novel therapeutics in the treatment of disease of lipid and/or glucose metabolism
US20090131714A1 (en) 2005-06-08 2009-05-21 Krasutsky Pavel A Synthesis of betulonic and betulinic aldehydes
US7718635B2 (en) 2005-06-10 2010-05-18 Pola Chemical Industries Inc. Triterpenic acid derivative and preparation for external application for skin comprising the same
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
WO2007078848A2 (en) 2005-12-16 2007-07-12 Panacos Pharmaceuticals, Inc. Preparation of pharmaceutical salts of 3-o-(3',3'-dimethlsuccinyl) betulinic acid
EP1803461A1 (en) 2005-12-27 2007-07-04 Heinz-Herbert Fiebig Therapeutic use of an extract from the leaves of Nerium oleander
GB0604535D0 (en) 2006-03-07 2006-04-12 Sndv Sprl Betulonic acid derivatives
US20090203661A1 (en) 2006-10-12 2009-08-13 Safe Stephen H Betulinic acid, derivatives and analogs thereof and uses therefor
AR063546A1 (es) 2006-11-03 2009-01-28 Panacos Pharmaceuticals Inc DERIVADOS DE TRITERPENO, METODOS PARA SU PREPARACION, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE INFECCIoN POR EL VIRUS VIH.
WO2008091532A1 (en) 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US8987212B2 (en) 2007-08-07 2015-03-24 Muhammed Majeed Oleanoyl peptide composition and method of treating skin aging
RU2571687C2 (ru) 2007-11-13 2015-12-20 Феникс Байотекнолоджи Инк. Набор для определения вероятности терапевтического ответа на противораковую химиотерапию сердечным гликозидом
TW201004627A (en) 2008-04-18 2010-02-01 Reata Pharmaceuticals Inc Antioxidant inflammation modulators: novel derivatives of oleanolic acid
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
DK2276493T3 (da) 2008-04-18 2019-01-02 Reata Pharmaceuticals Inc Antioxidative inflammationsmodulatorer: oleanolsyrederivater med amino- og andre modifikationer ved c-17
CA2721666C (en) 2008-04-18 2017-05-23 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: c-17 homologated oleanolic acid derivatives
US20110224159A1 (en) 2008-09-10 2011-09-15 Universite du Quebec a Chicoutime Bidesmosidic betulin and betulinic acid derivatives and uses thereof as antitumor agents
AU2009303460B9 (en) 2008-10-14 2014-12-18 Nerium Biotechnology, Inc. Process for extracting cardiac glycodides and compositions
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
WO2010144611A2 (en) 2009-06-10 2010-12-16 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
CN101704872B (zh) 2009-11-23 2012-06-27 张南 23-羟基白桦酸衍生物、其制备方法及应用
US8685469B2 (en) 2009-11-30 2014-04-01 University Of Kwazulu-Natal In vitro anti-sickling activity of betulinic acid, oleanolic acid and their derivatives
US9011937B2 (en) 2010-11-22 2015-04-21 Phoenix Biotechnology, Inc. Method of treating neurological conditions with extract of Nerium species or Thevetia species
KR101811462B1 (ko) 2010-01-11 2018-01-25 피닉스 바이오테크놀러지 인코포레이티드. 협죽도 추출물을 포함하는 신경질환 치료용 조성물
US10383886B2 (en) 2010-01-11 2019-08-20 Phoenix Biotechnology, Inc. Method of treating neurological conditions with oleandrin
TWI386415B (zh) 2010-02-02 2013-02-21 Univ Kaohsiung Medical 熊果酸衍生物及其醫藥組合物
TWI410431B (zh) 2010-12-22 2013-10-01 Ind Tech Res Inst 齊敦果酸衍生物在製備預防或治療ｃ型肝炎之藥物的用途
WO2012095705A1 (en) 2011-01-10 2012-07-19 Hetero Research Foundation Pharmaceutically acceptable salts of novel betulinic acid derivatives
US8748415B2 (en) 2011-01-31 2014-06-10 Bristol-Myers Squibb Company C-28 amines of C-3 modified betulinic acid derivatives as HIV maturation inhibitors
CN102558280B (zh) 2011-11-18 2014-09-17 温州大学 一种30-卤代桦木酸的生产方法
DK2787002T3 (en) 2011-12-01 2016-08-29 Hangzhou Bensheng Pharmaceutical Co Ltd Oleanolsyreamidat derivatives, methods of making and uses thereof
WO2013079018A1 (zh) 2011-12-01 2013-06-06 杭州本生药业有限公司 2-位取代的齐墩果酸衍生物、及其制备方法和应用
WO2013160810A2 (en) 2012-04-24 2013-10-31 Hetero Research Foundation Novel betulinic acid derivatives as hiv inhibitors
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
KR101889528B1 (ko) 2012-08-14 2018-08-17 넥스올리고(주) 신규한 우르솔릭산 유도체 및 이의 제조 방법
DK2892912T3 (da) 2012-09-10 2019-06-24 Reata Pharmaceuticals Inc C17-alkandiyl og alkenediylderivater af oleanolsyre og fremgangsmåder til anvendelse deraf
EP2892911B1 (en) 2012-09-10 2017-08-30 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
WO2014040073A1 (en) 2012-09-10 2014-03-13 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
WO2014105926A1 (en) 2012-12-31 2014-07-03 Hetero Research Foundation Novel betulinic acid proline derivatives as hiv inhibitors
AU2014218754B2 (en) 2013-02-25 2017-04-20 VIIV Healthcare UK (No.5) Limited C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of HIV
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
WO2017214080A1 (en) * 2016-06-09 2017-12-14 University Of Massachusetts Inhibition of zika virus infection
ES2874187T3 (es) 2016-09-14 2021-11-04 Phoenix Biotechnology Inc Método y composiciones para el tratamiento de una infección viral
US10702567B2 (en) * 2016-09-14 2020-07-07 Phoenix Biotechnology, Inc. Method and compositions for treating viral infection
US10596186B2 (en) 2016-09-14 2020-03-24 Phoenix Biotechnology, Inc. Method and compositions for treating viral infections
MX2020002883A (es) 2017-09-14 2020-10-05 Phoenix Biotechnology Inc Método y composiciones para tratar la infección viral.

Also Published As

Publication number Publication date
MX2020009095A (es) 2022-07-28
TW202211926A (zh) 2022-04-01
IL277315A (en) 2021-09-30
KR20210124010A (ko) 2021-10-14
RU2020130238A3 (zh) 2022-03-14
TWI753747B (zh) 2022-01-21
JP2022186737A (ja) 2022-12-15
WO2021201903A1 (en) 2021-10-07
IL277315B (en) 2022-05-01
TW202137991A (zh) 2021-10-16
TWI790048B (zh) 2023-01-11
JP7153083B2 (ja) 2022-10-13
MX2022009176A (es) 2022-08-17
IL291727B1 (en) 2023-03-01
SG11202105728YA (en) 2021-11-29
IL291727A (en) 2022-05-01
JP2022522074A (ja) 2022-04-14
RU2020130238A (ru) 2022-03-14
KR102464428B1 (ko) 2022-11-04
IL291727B2 (en) 2023-07-01

Similar Documents

Publication Publication Date Title
US10729735B1 (en) Method and compostitions for treating coronavirus infection
KR102464428B1 (ko) 코로나바이러스 감염 치료를 위한 방법 및 조성물
US11013776B2 (en) Method and compositions for treating viral infection
ES2965161T3 (es) Método y composiciones para el tratamiento de infección por coronavirus
US20220054521A1 (en) Method and Compositions for Treating Coronavirus Infection
EP4009981B1 (en) Method and compositions for treating coronavirus infection
US20220047616A1 (en) Method and Compositions for Treating HTLV-1 Virus Infection
AU2021201209B2 (en) Method and compositions for treating coronavirus infection
US11806359B2 (en) Method and compositions for treating Coronavirus infection

Legal Events

Date Code Title Description
A107 Divisional application of patent
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right